This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Vitamin D Supplementation on Blood Pressure and HbA1c Levels in Patients With T2D

This study has been completed.
Information provided by (Responsible Party):
Reto Krapf, Kantonsspital Bruderholz Identifier:
First received: April 23, 2012
Last updated: April 24, 2012
Last verified: April 2012
The effect of administration of vitamin D is tested on the long-term control of blood sugar (as measured by HbA1-c levels in blood) and mean blood pressure (as measured by 24 hour blood pressure profiles)in patients with stable type 2 diabetes mellitus

Condition Intervention Phase
Diabetes Mellitus Type 2 Drug: 25(OH) vitamin D Drug: 0.9 % NaCl Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Administration of 25(OH) Vitamin on Mean 24 Hour Blood Pressure and HBA1c Levels in Patients With Stable Type 2 Diabetes Mellitus

Resource links provided by NLM:

Further study details as provided by Reto Krapf, Kantonsspital Bruderholz:

Primary Outcome Measures:
  • Change in HBA1-c levels [ Time Frame: 3 and 6 months ]
  • 24 hour mean blood pressure [ Time Frame: 3 and 6 months ]

Secondary Outcome Measures:
  • plasma glucose [ Time Frame: 3 and 6 months ]
  • HOMA [ Time Frame: 6 months ]

Enrollment: 51
Study Start Date: January 2009
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: vitamin D
Intervention: Intramuscular injection of 300 000 U of 25(OH)vitamin D
Drug: 25(OH) vitamin D
300 000 U intramuscularly, one dosage, in subjects with 25 (OH) vit D levels below 80 nmol/L, another dosage of 150 000 U after 3 months if 25(OH)vit D levels continue to be below 80 nmol/L.
Placebo Comparator: placebo
administration of 0.9 % NaCl as a placebo
Drug: 0.9 % NaCl
1 ml of 0.9 % of NaCl at the beginning and 0.5 ml of 0.9 % NaCl after three months


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Men and women, ages ≥18 years
  • Official diagnostic criteria for type 2 diabetes fulfilled in patients on any type of oral or parenteral glucose-lowering treatment
  • Independent living at home
  • On stable regimen of BP meds (if any) with BP well controlled and/or K supplement (if any) for 2 months and which is deemed unlikely to change during the study
  • Stable glucose control for 2 months by any approved method including insulin

Exclusion criteria

  • Patients with type 1 diabetes (or insulin-requiring diabetes of unclear type)
  • Patients on hemodialysis, with hyperparathyroidism or active cancer disease
  • Patients with known metabolic bone disease
  • Laboratory evidence of kidney (eGFR < 60 ml/min) or liver disease
  • Dietary calcium intake exceeding 1500mg/d (as estimated by dietary history)
  • 25(OH) vitamin D levels at baseline > 70 nmol/L
  • Calciuria (> 8 mmol/24 hours as measured by 24 hour urine collections)
  • Hypo- and hypercalcemias and hypo- and hyperphosphatemias of any cause
  • Medications that affect vitamin D metabolism (e.g. antiepileptic drugs, calcimimetics, 1-34 PTH (Forsteo) vitamin D therapy over and above 400U daily 6 months prior to enrollment and during the study)
  • Foreseeable need for adaptation of either glucose- or blood pressure lowering during the next 6 months as decided by the family physician or the treating diabetologist - see above
  • History of binge eating or wt gain or loss exceeding 6 kg in past 18 months
  • Patients on any type of inhibitors of plasma coagulation (i.e. coumarine, heparins)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01585051

Department of medicine, Kantonsspital Bruderholz
Bruderholz/Basel, Basel-Landschaft, Switzerland, CH-4101
Sponsors and Collaborators
Kantonsspital Baselland Bruderholz
Principal Investigator: Reto Krapf, MD Department of Medicine, Kantonsspital Bruderholz, University of Basel, Switzerland
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Reto Krapf, Professor of Medicine, Kantonsspital Bruderholz Identifier: NCT01585051     History of Changes
Other Study ID Numbers: x335/08
Study First Received: April 23, 2012
Last Updated: April 24, 2012

Keywords provided by Reto Krapf, Kantonsspital Bruderholz:
vitamin D
blood pressure
typ 2 diabetes mellitus
blood glucose

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on August 18, 2017